Recently, an inhibitor of mutant forms of IDH1 and IDH2 has been synthesized (vorasidenib) and has been approved by the Food and Drug Administration for grade 2 IDH-mutant glioma under the name VORANIGO (21). Here, IDH2 is linked to central nervous system cancer.